Identification of a sex-specific genetic signature in dementia with Lewy bodies: a meta-analysis of genome-wide association studies

Elizabeth Gibbons(Van Andel Institute), Arvid Rongve(Privatsykehuset Haugesund), Itziar de Rojas(Instituto de Salud Carlos III), Alexey Shadrin(Oslo University Hospital), Kaitlyn Westra(Van Andel Institute), Allison Baumgartner(University of North Carolina at Chapel Hill), Levi Rosendall(Van Andel Institute), Zachary Madaj(Van Andel Institute), Dena Hernández(National Institute on Aging), Owen A. Ross(WinnMed), Valentina Escott‐Price(Cardiff University), Claire E. Shepherd(UNSW Sydney), Laura Parkkinen(Nuffield Orthopaedic Centre), Sonja W. Scholz(National Institutes of Health), Juan C. Troncoso(Johns Hopkins University), Olga Pletniková(Johns Hopkins University), Ted M. Dawson(Johns Hopkins University), Liana S. Rosenthal(Johns Hopkins University), Olaf Ansorge(Nuffield Orthopaedic Centre), Jordi Clarimón(Universitat Autònoma de Barcelona), Alberto Lleó(Universitat Autònoma de Barcelona), Estrella Morenas‐Rodríguez(Universitat Autònoma de Barcelona), Lorraine N. Clark(Columbia University), Lawrence S. Honig(Columbia University), Karen Marder(Columbia University), Afina W. Lemstra(University Medical Center), Ekaterina Rogaeva(University of Toronto), Peter St George‐Hyslop(University of Toronto), Elisabet Londos(Lund University), Henrik Zetterberg(UK Dementia Research Institute), Kevin Morgan(University of Nottingham), Claire Troakes(King's College - North Carolina), Safa Al‐Sarraj(King's College - North Carolina), Tammaryn Lashley(National Hospital for Neurology and Neurosurgery), Janice L. Holton(National Hospital for Neurology and Neurosurgery), Yaroslau Compta(Neuroscience Institute), Vivianna M. Van Deerlin(University of Pennsylvania), Geidy E. Serrano(Banner Sun Health Research Institute), Thomas G. Beach(Banner Sun Health Research Institute), Suzanne Lesage(Centre National de la Recherche Scientifique), Douglas Galasko(University of California San Diego), Eliezer Masliah(National Institute on Aging), Isabel Santana(Hospitais da Universidade de Coimbra), Pau Pástor(Biomedical Research Networking Center on Neurodegenerative Diseases), Mónica Díez-Fairén(Biomedical Research Networking Center on Neurodegenerative Diseases), Miquel Aguilar(Biomedical Research Networking Center on Neurodegenerative Diseases), Marta Marquié(Fundació ACE), Pablo García‐González(Fundació ACE), Clàudia Olivé(Fundació ACE), Raquel Puerta(Fundació ACE), Amanda Cano(Fundació ACE), Óscar Sotolongo‐Grau(Fundació ACE), Sergi Valero(Fundació ACE), Vanesa Pytel(Fundació ACE), Maitée Rosende‐Roca(Fundació ACE), Montserrat Alegret(Fundació ACE), Lluís Tárraga(Fundació ACE), Merçé Boada(Fundació ACE), Ángel Carracedo(Universidade de Santiago de Compostela), Emilio Franco‐Macías(Instituto de Biomedicina de Sevilla), Jordi Pérez‐Tur(Instituto de Biomedicina de Valencia), José Luís Royo(Universidad de Málaga), José María García‐Alberca(Instituto de Neurociencias), Luís Miguel Real(Hospital Universitario de Valme), María Eugenia Sáez(Centro Andaluz de Biología del Desarrollo), María J. Bullido(Centro de Biología Molecular Severo Ochoa), Miguel Calero(Instituto de Salud Carlos III), Miguel Medina(Instituto de Salud Carlos III), Pablo Mir(Instituto de Biomedicina de Sevilla), Pascual Sánchez‐Juan(Biomedical Research Networking Center on Neurodegenerative Diseases), Victoria Álvarez(Hospital Universitario Central de Asturias), Kayenat Parveen(University Hospital Bonn), Kumar Parijat Tripathi(University of Cologne), Stefanie Heilmann‐Heimbach(University of Bonn), Alfredo Ramı́rez(University of Cologne), Pentti J. Tienari(University of Helsinki), Olivier Bousiges(Laboratoire de Biochimie), Frédéric Blanc(Université de Strasbourg), Chiara Fenoglio(University of Milan), Alessandro Padovani(University of Brescia), Barbara Borroni(University of Brescia), Andrea Pilotto(University of Brescia), Flavio Nobili(University of Genoa), Ingvild Saltvedt(Norwegian University of Science and Technology), Tormod Fladby(University of Oslo), Geir Selbæk(Oslo University Hospital), Ingunn Bosnes(Norwegian University of Science and Technology), Geir Bråthen(Norwegian University of Science and Technology), Annette M. Hartmann(Wittenberg University), Afina W. Lemstra(Amsterdam Neuroscience), Dan Rujescu(Wittenberg University), Brit Mollenhauer(Paracelsus Elena Klinik Kassel), Byron Creese(University of Exeter), Marie‐Christine Chartier‐Harlin(Inserm), Lavinia Athanasiu(Oslo University Hospital), Srdjan Djurovic(Oslo University Hospital), Leonidas Chouliaras(University of Cambridge), John T. O’Brien(University of Cambridge), Liisa Myllykangas(University of Helsinki), Minna Oinas(University of Helsinki), Tamás Révész(National Hospital for Neurology and Neurosurgery), Andrew Lees(National Hospital for Neurology and Neurosurgery), Bradley F. Boeve(Mayo Clinic in Arizona), Ronald C. Petersen(Mayo Clinic in Arizona), Tanis J. Ferman(WinnMed), Caroline Graff(Mayo Clinic in Arizona), Nigel J. Cairns, John C. Morris, Glenda M. Halliday(The University of Sydney), John Hardy, Dennis W. Dickson(WinnMed), Andrew Singleton(National Institute on Aging), David J. Stone(Cerevel Therapeutics (United States)), Ole A. Andreassen(Oslo University Hospital), Agustı́n Ruiz(Instituto de Salud Carlos III), Dag Aarsland(King's College - North Carolina), Rita Guerreiro(Van Andel Institute), José Brás(Van Andel Institute)
medRxiv
November 22, 2022
Cited by 5Open Access
Full Text

Abstract

Abstract Background Genome-wide Association Studies (GWAS) have reshaped our understanding of the genetic bases of complex diseases in general and neurodegenerative diseases in particular. Despite being a common disorder, dementia with Lewy bodies (DLB), which, together with Parkinson’s disease dementia (PDD), comprise the umbrella term Lewy body dementias (LBD), is far from being well-characterized genetically. This is primarily due to a lack of familial cases and difficulty recruiting large, deeply characterized cohorts, given the high rate of misdiagnosis. By performing the largest GWAS in DLB, we aimed to identify novel risk loci to gain a better understanding of this disease’s pathobiology. Methods Here, we conducted the largest meta-analysis of genome-wide association studies performed in LBD, using a total of 5,119 cases and 20,988 controls, from five independent datasets, aggregating all previously published DLB genome-wide association results to date, as well as two previously undescribed cohorts. Additionally, we performed a sex stratified GWAS using the discovery datasets. We updated the heritability estimates for DLB and, to fine map these estimates, we used local heritability analysis. We calculated genetic correlation estimates between DLB and a range of other diseases and traits to identify potential pleiotropy. We also performed gene-set analysis to identify genes with excess burden of rare variability and pathway analysis. Lastly, we used the UK Biobank data to perform a PheWas using individuals at the extremes of genetic risk for DLB. Findings Between November 2018 and September 2022 we analyzed 8.6 million single nucleotide polymorphisms in 3293 DLB cases, 1826 LBD cases and 20,988 controls, as well as phenotypes from the UK Biobank dataset. Despite more than doubling the sample size from the previous GWAS in DLB, we did not identify significant loci in addition to those previously reported at GBA, SNCA, STX1B , and APOE . However, the sex-stratified analysis revealed that the GBA and SNCA signals are mainly driven by males, suggesting a sex-specific genetic architecture of disease. Using only clinical and neuropathologically diagnosed cases, we highlight four loci surpassing the significance threshold. Using the largest cohort of DLB we update our heritability estimates to 13% and fine map these results highlighting regions of the genome with high heritability but no genome-wide significant result so far. Interpretation These data provide the most comprehensive analysis of genetic variability in DLB to date. The fact that no novel risk loci have been identified after doubling the cohort size indicates the potentially significant role of rare variants in the genetic architecture of DLB and stresses the urgent need for larger, well-characterized cohorts of this disease for genetic studies. The sex-stratified analysis shows that males and females have different signatures of genetic risk for DLB. These results have widespread implications for clinical practice and clinical trials’ design in DLB.


Related Papers

No related papers found

Powered by citation graph analysis